Locus Biosciences
Locus Biosciences raises $152M Series C at $600M valuation
Quick Facts
Locus Biosciences: Series C Funding Round
Locus Biosciences has successfully raised $152M in Series C funding, reaching a valuation of $600M.
Company Overview
CRISPR-edited bacteriophages
Funding Details
The Series C round was led by Johnson & Johnson, with participation from Longitude Capital, Braeburn Capital, Domain Associates.
Company Information
- Headquarters: 9201 University City Boulevard, Charlotte, NC 28223
- Founded: 2015
- Employees: 150+
- Category: Biotech
Investment
Locus Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson: Verified investor in Series C
- Longitude Capital: Verified investor in Series C
- Braeburn Capital: Verified investor in Series C
- Domain Associates: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...